Form 4: Emergent BioSolutions Executive Receives RSU Grant

SVP of Bioservices William Hartzel was granted 100,111 restricted stock units following shareholder approval of the company's incentive plan.

Summary

• William Hartzel, SVP of Bioservices at Emergent BioSolutions, acquired 100,111 restricted stock units (RSUs).
• The grant was originally approved by the Compensation Committee on March 2, 2026, contingent on shareholder approval of the Amended Stock Incentive Plan.
• Shareholders approved the plan on April 29, 2026, triggering the issuance of the units.
• The RSUs vest in three equal annual installments, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company strategy or financial performance.

Positives

• Alignment of executive compensation with long-term shareholder interests through equity-based incentives.
• Successful shareholder approval of the Amended Stock Incentive Plan, providing the company with necessary tools for talent retention.

Negatives

• The issuance of 100,111 RSUs results in potential future dilution for existing shareholders.

Risks

• Vesting is contingent upon continued service, creating potential retention risk if the executive departs before the three-year period concludes.

Future Outlook

The RSUs will vest in three annual installments, incentivizing the executive to remain with the company over the next three years.

Management Comments

• The grant is subject to the terms of the Amended Stock Incentive Plan and the specific grant agreement.

Industry Context

StockSavvy.ai notes that equity-based compensation remains a standard practice in the biotechnology sector to align executive performance with corporate milestones and shareholder value.

Comparison to Industry Standards

• The use of three-year vesting schedules for executive RSUs is consistent with standard corporate governance practices in the U.S. biotech industry.
• Granting equity following shareholder approval of incentive plans is a standard regulatory requirement for publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual vesting and conversion of these units into common stock.

Next Steps

• Vesting of the first installment of the 100,111 RSUs on the first anniversary of the approval date.

Key Dates

Keywords

Emergent BioSolutions, EBS, Insider Transaction, Restricted Stock Units, Executive Compensation, Form 4